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Figures	
Figure	1:	The	influence	of	selection	in	the	cancer	genome.		A:	A	simulated	distribution	of	variant	allele	frequencies	(VAF)	in	a	cancer	that	is	evolving	neutrally.		These	VAF	distributions	are	naturally	produced	by	next	generation	genome	sequencing.			The	distribution	has	a	peak	around	0.5	–	these	are	the	clonal	variants	present	in	all	cancer	cells.		The	distribution	of	subclonal	variants	(those	at	lower	frequencies)	follows	a	‘1/f’	distribution	whereby	there	are	ever	many	more	mutations	at	ever-lower	frequency.		Neutral	cancer	evolution	can	be	detected	by	comparing	the	observed	distribution	of	mutation	frequencies	in	a	cancer	to	this	expected	theoretical	distribution.		B:	VAF	distribution	for	an	in	silico	model	of	a	cancer	where	a	fitter	subclone	has	clonally	expanded	within	the	tumour.		The	cluster	of	mutations	within	the	subclone	are	‘passenger’	mutations	dragged	along	to	higher	frequency	within	the	tumour	during	the	clonal	expansion.		Even	though	there	is	selection,	there	is	still	a	‘background’	of	neutral	evolution	–	this	is	the	neutral	evolution	within	the	selected	subclone	and	in	the	residual	tumour	cells.		
Figure	2:	Punctuated	equilibrium	and	hopeful	monsters.		A:	Mutations	accumulate	within	small	spatially	isolated	niches	(here	an	intestinal	crypt	is	depicted)	and	only	after	a	sufficient	number	of	adaptive	mutations	are	acquired	is	a	clonal	expansion	initiated.		From	a	macroscopic	perspective,	the	evolution	of	the	neoplasia	appears	punctuated,	even	though	the	driver	mutations	were	acquired	gradually	within	the	crypt.		B:	The	generation	of	a	hopeful	monster	–	a	clone	with	a	grossly	altered	genotype	–	in	a	single	cell	division	produces	a	neoplastic	in	a	single	‘catastrophic’	step.		
Figure	3:	Primary	data	indicating	punctuated	copy	number	evolution.	Copy-number	profiles	of	individual	breast	cancer	cells	from	a	single	breast	cancer	case	showing	the	same	grossly	altered	genomes	are	observed	in	all	cells	sampled,	and	no	intermediate	forms	are	detected.		Image	scaled,	cropped	and	reprinted	with	permission	from	ref.	[72].		
	
	 	
Box:	Definition	of	terms	
Neutral	evolution–	evolution	where	all	individuals	in	the	population	have	equal	fitness.		In	a	growing	population	(like	a	newly	formed	tumour)	this	means	that	all	cells	grow	at	the	same	rate.		
Drift	–	stochastic	effects	(e.g.	random	cell	death	in	a	tumour)	can	cause	some	‘lucky’	individuals	in	a	population	to	have	more	offspring	than	another,	and	so	the	‘lucky	lineage’	increases	in	size.		Consequently	drift	can	cause	fluctuations	in	subclone	size	in	the	absence	of	selection.		
Selection	–	the	process	that	results	in	one	individual	in	a	population,	because	of	its	particular	well-adapted	traits,	having	more	offspring	than	another	less	well-adapted	individual.		
Fitness	–	the	relative	ability	of	an	individual	to	produce	surviving	offspring	in	a	population.			
Punctuated	equilibrium	–	the	process	whereby	apparently	abrupt	changes	in	phenotype	of	the	population	at	large	occur	because	of	gradual	evolution	in	small	spatially	isolated	niches.		
Hopeful	monster/saltation	–	the	process	whereby	abrupt	changes	in	phenotype	are	cause	by	underlying	(large	scale)	punctuated	changes	in	the	genome.		In	cancer,	massive	genome	alterations	occurring	in	a	single	cell	division	are	examples	of	saltatory	genome	evolution.						
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